Human lung fibroblasts (HLF) express high levels of the LPA 1 receptor, a GPCR that responds to the endogenous lipid mediator, lysophosphatidic acid (LPA). Several molecular species or analogues of LPA exist and have been detected in biological fluids such as serum and plasma. The most widely expressed of the LPA receptor family is the LPA 1 receptor, which predominantly couples to G q/11 , G i/o and G 12/13 proteins. This promiscuity of coupling raises the possibility that some of the LPA analogues may bias the LPA 1 receptor towards one signalling pathway over another.
Introduction
Lysophosphatidic acid (1-acyl-2-hydroxy-sn-glycero-3-phosphate; LPA) belongs to a family of endogenous lipid molecules involved in a number of cellular processes including proliferation, apoptosis and migration. LPA exerts these biological effects through highly efficacious interactions with its corresponding GPCRs, the LPA family of receptors, leading to downstream intracellular signalling events. The most widely expressed is the LPA 1 receptor, which predominantly couples to G q/11 and G i/o , as well as G 12/13 , leading to calcium mobilization and the inhibition of cAMP generation . This can lead to diverse cellular processes such as cell proliferation, actin cytoskeletal rearrangement and neurite retraction (Contos et al., 2000) .
Several molecular species or analogues of LPA exist, which have varying carbon chain lengths and degrees of saturation, and these LPA analogues have been detected in biological fluids such as serum and plasma, linked to either the sn-1 or sn-2 glycerol backbone. The major analogues of LPA found in human blood are those with fatty acid (acyl) chains of 16, 18 and 20 carbon atoms, with 86% of LPA in serum consisting of 18:1, 18:2 and 20:4 LPA (the numbers :1, :2, :4 refer to the number of double bonds in the acyl chain). These are found at high nanomolar concentrations in the plasma but can exceed 10 μM in serum (Baker et al., 2001; Lin et al., 2010) .
The LPA 1 receptor predominantly signals through G i/o and G q/11 proteins to increase levels of intracellular calcium but has also been shown to couple to G 12/13 (Fukushima et al., 1998; Alexander et al., 2015) . This promiscuous coupling means that agonists at the LPA 1 receptor have the potential to demonstrate signalling bias, if they stabilize distinct conformations of the receptor that can differentially activate distinct G proteins leading to disparate functional end points. This phenomenon of agonist-biased signalling has been described for a number of different synthetic ligands at GPCRs, where the endogenous ligand is used as the unbiased comparator ligand (see Rajagopal et al., 2010; Kenakin and Miller, 2010) . To date, the majority of these studies have been performed in cell lines that recombinantly express the receptors of interest (Berg et al., 1998; Cordeaux et al., 2001; Gay et al., 2004; Lane et al., 2007; Rosethorne and Charlton, 2011) . These are useful systems to examine signal bias as responses can be directly attributed to the receptor being over-expressed. However, some receptors also elicit different responses dependent upon the cell type in which they are expressed, due to the presence of a different complement of signalling molecules. For example, studies in mammalian cells indicate that unsaturated LPA analogues have lower EC 50 values than fully saturated analogues (Fujiwara et al., 2005) , whereas in human A431 cells, no correlation between degree of saturation and potency was observed (Jalink et al., 1995) . The different analogues of LPA will possess a range of physicochemical properties, depending upon the structure of the acyl chain, most notably in their solubility and tendency to form micelles. This may contribute to the range of biological activities that have been reported for these molecules. The diversity of the LPA analogues and the range of signalling molecules available to the LPA 1 receptor therefore represent a useful system in which to examine agonist-bias within endogenous ligands.
We therefore aimed to determine whether any signal bias could be detected with the different LPA analogues acting at an endogenously expressed LPA 1 receptor in primary human lung fibroblasts (HLF). This may have implications in pathophysiological processes as the activation of different G proteins by the range of endogenous ligands present in serum and plasma may result in diverse cellular responses.
Methods
Cell culture and maintenance of HLF HLF (from PromoCell, Heidelberg, Germany and Lonza, Slough, UK) were maintained in DMEM containing high glucose and HEPES, supplemented with heatinactivated FBS (10% v/v), penicillin (100 iu·mL À1 ), streptomycin (100 μg·mL À1 ) and sodium pyruvate (1 mM). Starve medium was the same as growth medium but without FBS. 
Tables of Links

Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Power calculations were used to determine that sample size required is >1. Results are expressed as the mean AE SEM from three separate experiments, run in duplicate. Graphs were fitted to data and statistical analysis performed using GraphPad Prism (V7.00 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com). Concentration-response data were fitted using a four-parameter logistic equation. IC 50 values obtained from the inhibition curves were converted to K i values using the method of Cheng and Prusoff (1973) . The Pearson correlation coefficient (r) was determined using the standard correlation function in GraphPad Prism, followed by a two-tailed t-test to determine significance. All statistical tests used P ≤ 0.05 as critical level of significance. The ability of an agonist to cause a functional response after binding to a receptor is known as the transduction coefficient (transduction ratio) and is a function of both the binding affinity (K A ) and the efficacy (τ) of the ligand. To compare agonist responses between different assays, the Log(τ/K A ) or LogR was calculated using the Operational model of agonism (for details, see Van Der Westhuizen et al., 2014) . For the purposes of this analysis, only the log of the ratio (LogR) between K A and τ [Log(τ/K A )] was calculated for each agonist at each pathway, as bias can arise through differences in either affinity or efficacy. The responses to all agonists at each pathway were globally fitted with the parameters of basal, E max and n shared for all agonists. For full agonists, K A was constrained to >0 and estimated directly from curve fitting for partial agonists.
For estimation of observational bias for the different assays, the LogR for each compound was compared with the LogR for the 'neutral' compound 18:1 LPA (or 17:0), using equation (1).
Ligand bias (ΔΔLogR) was calculated using the difference between the ΔLogR values derived for each pathway using equation 1, and from this, the bias factor for each compound was calculated from equation (3).
where L1 is ligand 1, P1 is pathway 1, L2 is ligand 2 and P2 is pathway 2.
Bias factor ¼ 10
Materials
The LPA analogues tested were purchased from Avanti Polar Lipids (Alabaster, ALA) or Echelon Biosciences (Salt Lake City, UT). Purity of the LPA analogues was stated to be >99% LPA (see Table S1 for details). All stock solutions were made up to 10 mM in water and stored at À20°C. 
Results
LPA receptor expression
To determine which of the LPA receptors are present at significant levels in HLF, a Taqman assay quantifying the endogenous expression of the different LPA receptors was performed. The relative expression of each receptor was compared with the housekeeping gene hypoxanthine phosphoribosyltransferase 1 (HPRT1). The LPA 1 receptor had the highest level of expression in the HLF (4.4 AE 1.5-fold relative expression compared with HPRT; Figure S1 ), while the other receptors tested had no measurable expression in these cells (<0.1-fold relative expression compared with HPRT). Based on the expression data, we used the HLF to investigate LPA 1 receptor-mediated signalling of different molecular analogues of LPA.
Calcium mobilization
To investigate the intracellular signalling downstream of the LPA 1 receptor, we first monitored calcium mobilization in HLF after treatment with a range of concentrations of eleven LPA analogues. These eleven analogues can be divided into four sub-groups, comprising three sub-groups of fatty acid esters, the shorter chain (14:0, 16:0 and 17:0) and the longer chain, 18:x, 20:x esters along with the ether analogues C18: x LPA (see Table S1 for chemical structures). The most quantitatively abundant forms of LPA in human plasma are 16:0, 18:2 and 18:1 LPA. The last form (18:1 LPA) is perhaps the most commonly used laboratory reagent for signalling studies; therefore, it was used as a positive control in these experiments (Choi et al., 2010) .
All LPA analogues increased intracellular calcium mobilization in a concentration-dependent manner, with a range of potencies and intrinsic activities (Figure 1 ). Of these, C18:1 was the most potent form of LPA, despite having modest intrinsic activity (77%), with the fully saturated 20:0, C18 and 17:0 as the least potent LPAs. All analogues except for 20:4, 18:3, C18:1, C18 and 20:0 were fully efficacious, with E max values comparable to that of 18:1 LPA (Table 1) . Among the 18: LPAs tested, a general trend was observed where an increase in the degree of saturation of the 18: LPAs resulted in an increase in both potency and intrinsic activity in the calcium mobilization assay. In contrast, among the 20:x and C18:x LPAs tested, the fully saturated 20:0 and C18:0 were the least potent and gave only partial responses in this assay.
ERK phosphorylation
As both G q/11 and G i/o have been shown to activate ERK (Goldsmith and Dhanasekaran, 2007) , we explored the ability of the same range of LPA analogues to phosphorylate Figure 1 Concentration-response curves for calcium mobilization in HLF using (A) short chain (B) 18:x, (C) 20:x and (D) C18:x molecular analogues of LPA. Data were normalized to the 18:1 LPA response and are expressed as means AE SEM for three independent experiments.
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ERK in the primary HLF. In order to determine the correct incubation time for this assay, we first performed a time course of ERK phosphorylation with 18:1 LPA (data not shown). The pERK response was rapid and short-lived, with maximal response achieved between 2 and 5 min after which time signal returned to basal levels. For this reason, all further experiments were performed after 5 min stimulation.
All of the LPA analogues were able to promote ERK phosphorylation with a range of intrinsic activities and potencies (Figure 2 ). The 18:1 LPA gave the largest maximal response, so this was taken to be 100% in these assays. In comparison, all other analogues of LPA tested were partial agonists in the pERK assay, with maximal responses ranging from 25 to 80% of that of 18:1 LPA (Table 1 ). The 20:0 and C18 LPA 
Figure 2
Concentration-response curves for ERK phosphorylation in HLF using (A) short chain (B) 18:x, (C) 20:x and (D) C18:x molecular analogues of LPA.
Cell intensity was normalized to the 18:1 LPA response and data expressed as means AE SEM for three independent experiments.
analogues were the least active in the pERK assay, able to only partly phosphorylate ERK at the highest agonist concentrations. Generally, most analogues of LPA had either similar (18:1, 18:3, 20:4) or slightly lower (5-10-fold) potency in the pERK compared with the calcium mobilization assay; however, 17:0 was more potent at pERK than calcium, and C18:1 was more than 20-fold more potent in the calcium assay than pERK. This suggested there was some bias in the ability of different analogues of LPA to signal to the two different pathways.
Quantification of ligand bias
Without truly understanding the difference in system and observational bias between the two assays, it is difficult to use agonist potency alone to determine which of the LPA analogues are biased and which are non-biased for the different systems being studied. For this reason, we attempted to quantify the level of ligand bias between the two pathways (calcium mobilization vs. ERK phosphorylation) using the operational model to calculate LogR or Log(τ/KA) for each ligand (Kenakin and Christopoulos, 2013; Van Der Westhuizen et al., 2014) . We then calculated the ΔLogR for each ligand, using 18:1 as the control ligand as this is one of the most abundant LPA analogues in the body and was the only agonist that gave a maximal response in both assays ( Figure 3 ; Table 1 ).
Comparison of the ΔLogR of each analogue of LPA between the two different assay formats revealed significant differences in the ΔLogR values between assays for 16:0, 17:0, 18:2 and C18:1 LPA (P < 0.05, unpaired t-test), which were selected for further investigation, comparing them with 18:1 LPA, as the non-biased, control ligand. In order to confirm that the responses observed were solely due to activation of the LPA 1 receptor, we tested this subset of LPA analogues against the selective LPA 1 receptor antagonist AM966 (Choi et al., 2010; Swaney et al., 2010) . AM966 was able to completely inhibit both calcium and pERK responses elicited by 18:1, 16:0, 17:0, 18:2 and C18:1 LPA (Figure 4) , demonstrating that the calcium response observed is solely due to activation of the LPA 1 receptor. IC 50 values derived from this assay were converted into K i using the Cheng-Prusoff equation (Table 2) .
Effect of PTx on calcium and pERK responses
It has been demonstrated previously that the LPA 1 receptor can couple to multiple pathways , of which both G i/o and G q/11 are capable of causing increases in intracellular calcium release and ERK phosphorylation. We hypothesized that the bias we observed between calcium mobilization and ERK phosphorylation for 16:0, 17:0, 18:2 and C18:1 LPA may be due to activation of different G proteins. To explore this further, the degree of calcium mobilization and ERK phosphorylation was determined after pretreatment of cells with PTx to inhibit G i/o proteins.
All LPA analogues tested were less potent in the calcium mobilization assay after 24 h treatment with PTx and demonstrated reduced intrinsic activity. In contrast, we were unable to accurately determine EC 50 in the ERK phosphorylation assay after PTx treatment, as pERK responses were almost abolished for all the analogues of LPA tested ( Figure 5 ; Table 3 ). From these data, we can infer that the calcium response is dependent on the activation of multiple G proteins, whereas the pERK response is predominantly PTx-sensitive. To explore the bias we observed for 16:0, 17:0, 18:2 and C18:1 LPA further, we wanted to quantify the signal bias between the total pERK response and the PTx-insensitive calcium response (data from experiments performed in the presence of PTx).
To do this, we fitted these data to the Operational model to calculate ΔΔLogR for each ligand between the two different pathways (for details see Van Der Westhuizen et al., 2014) . The results from this analysis (Table 4) demonstrate that for some of the molecular analogues, a bias for one particular signalling pathway does exist. Statistical analysis of the bias factors between both pathways, when compared with 18:1 LPA, showed that a significant difference was seen for 18:2 and 17:0 LPA, both of which appeared more biased towards the pERK pathway.
Discussion
The LPA 1 receptor is widely expressed in the body and has been implicated in diverse cellular and physiological responses, such as proliferation and survival, neurite retraction, brain development, renal and pulmonary fibrosis (Fukushima et al., 1998; Pradere et al., 2007; Estivill-Torrus et al., 2008; Tager et al., 2008) . The endogenous ligand, LPA, has many different naturally occurring analogues, which differ in chain length or saturation and are found within a range of biological fluids including serum and blood. The physiological relevance of this diversity is not fully appreciated. However, it may play an important role in pathology, as there is evidence that certain analogues may be differentially regulated in disease. For example, levels of the polyunsaturated 22:5 and 22:6 LPA are increased after allergen challenge in asthmatics (Park et al., 2013) , and patients with idiopathic pulmonary fibrosis demonstrated significantly higher levels of 22:4 LPA in their exhaled breath condensate compared with controls (Montesi et al., 2014) . It has also been demonstrated that there is a preference for polyunsaturated LPAs in the follicular Figure 3 Correlation between ΔLogR for calcium versus ERK phosphorylation in HLF. A Pearson correlation coefficient (r) was determined followed by a two-tailed t-test to determine significance (P ≤ 0.05).
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fluid of patients undergoing in vitro fertilization (Yamamoto et al., 2016) . In addition, 18:0, 18:1 and 16:0 LPA have been shown to increase in mouse spinal dorsal horn after nerve injury, with 18:1 LPA being the key species associated with amplification of LPA production in peripheral neuropathic pain (Ma et al., 2013) . The way in which these different analogues are regulated and signal within the body after activation of the LPA 1 receptor is still relatively poorly understood.
As well as having a number of endogenous LPA analogues to regulate LPA 1 receptor signalling, the receptor itself can also couple to multiple signalling pathways, including G i/o , G q/11 and G 12/13 proteins, to initiate diverse cellular responses (Fukushima et al., 1998) . For example, activation of LPA 1 receptors leads to ERK phosphorylation via the G i/o -Ras and eventually to gene transcription, cell cycle progression and proliferation (Kranenburg and Moolenaar, 2001) . Fibroblast chemotaxis to LPA has also been shown to occur via the PTx-sensitive G i/o proteins (Tager et al., 2008) , whereas the G 12/13 -RhoA pathway is responsible for actin cytoskeleton rearrangements in fibroblasts (Sakai et al., 2013) . In addition, the LPA receptor can transactivate EGF receptors, leading to ERK phosphorylation via G i/o -derived βγ sub units (Daub et al., 1996; Tveteraas et al., 2016) . In this study, we have investigated a number of different naturally occurring analogues of LPA, in terms of their activation of endogenous LPA 1 receptors in primary HLF. In addition to calcium mobilization, we have explored the ability of these ligands to activate the Ras-Raf-ERK signalling cascade resulting in ERK phosphorylation, which may occur downstream of either G i/o or G q/11 proteins (Goldsmith and Dhanasekaran, 2007) , or via G protein-independent mechanisms involving β-arrestin (Lefkowitz and Shenoy, 2005; Rosethorne and Charlton, 2011) . The signalling properties of the different LPA analogues were first characterized in the two assays, and PTx treatment used to determine the relative contributions of G i/o and G q/11 (G 12/13 ) proteins.
All analogues of LPA were capable of activating both pathways, with 18:1 LPA being the only fully efficacious agonist in both assays. The key difference observed in the responses between the assays was that all LPA analogues except 17:0 LPA were less potent in the pERK assay than the calcium mobilization assay.
In order to understand these differences, we first determined that all responses were due to only the LPA 1 receptor. Using the selective LPA 1 receptor antagonist AM966, we demonstrated that all responses were solely due to the activation of the LPA 1 receptor. We also observed that there were significant differences between the K i values determined from the two assays, with AM966 demonstrating consistently higher affinity at the pERK pathway when compared with calcium (twofold to sevenfold). This is most likely due to complications arising from non-equilibrium conditions in the rapid calcium signalling system. As the calcium assay is measured earlier than the pERK, it is likely that we are slightly underestimating the affinity of AM966 at this pathway due to these hemi-equilibrium conditions (Charlton and Vauquelin, 2010) .
All responses were AM966-dependent, suggesting that bias exists between the two signalling pathways downstream of the LPA 1 receptor. In order to explore the potential bias, we have attempted to control for differences in the kinetics of the different assays by taking the initial peak response for both assays. This occurred between 2 and 3 min for the Affinity of the LPA 1 receptor antagonist AM966 in calcium mobilization and ERK phosphorylation assays in the presence of a range of different LPA isoforms. Data were analysed in a pairwise manner using a two-tailed unpaired Student's t-test to determine if there was a significant difference in the affinity values between the two assays. Data are shown as means AE SEM for three independent experiments. *P < 0.05, significantly different from corresponding value for ERK phosphorylation. , 2015) . Although we cannot completely rule out a contribution of these processes, this suggests that the responses we are measuring will not be affected by differences in receptor state but are in fact due to differential activation of the pathways being measured. In order to quantify the potential bias demonstrated by the LPA analogues, functional assays for each pathway must be used, and the differences between kinetics, receptor reserve and signal amplification taken into account. The most common way to do this is to use a reference (usually endogenous) agonist that is assumed to be non-biased and relate experimental data to that obtained for the reference ligand. As all the ligands we have tested here are endogenous LPAs for the LPA 1 receptor, we have chosen to use 18:1 LPA as the control agonist, as it was the only analogue that was fully efficacious in both assays. We used the Operational model of agonism to calculate a LogR for each ligand, which is a combination of efficacy (τ) and affinity (K), both of which can contribute to ligand bias in a functional system. By comparing the LogR of each analogue to that of our control analogue, 18:1, we can eliminate any bias that may exist due to differences in the efficiency of receptor coupling to each second messenger. From this analysis, we chose to further explore the signalling profiles of 16:0, 17:0, 18:2 and C18:1 LPA, as they yielded LogR values that were significantly different between the two assay formats, indicating that they may be biased agonists.
For these selected agonists, we wanted to further explore the signal bias, by determining the role of G i/o proteins in each of the responses we have measured. To do this, we used PTx treatment to inactivate the G i/o subset of G proteins to determine what effect this would have on the calcium and pERK responses. ERK phosphorylation was almost completely inhibited after PTx treatment, while a significant proportion of the calcium response remained. This suggests that the calcium response is due to the activation of several G proteins, whereas the pERK response is predominantly PTx-sensitive and therefore may be due to G i/o protein activation.
For this reason, we repeated the LogR analysis using data for ERK phosphorylation (without PTx treatment) compared with the PTx-treated calcium responses. From these data, we observed a significant difference between the ΔΔLogR for 18:2 and 17:0 LPA, compared with 18:1, our control LPA, suggesting that these ligands are more biased towards the pERK pathway over the PTx-insensitive calcium response, compared with 18:1 LPA. To confirm that the ERK phosphorylation is occurring independent of G q/11 activation, and that the PTx-treated calcium responses are solely due to G q/11 activation, it would be interesting to repeat these experiments in the presence of selective G q inhibition or down-regulation of specific G proteins using siRNA treatment. Although we cannot rule out a role for LPA 1 receptor-mediated EGF transactivation leading to ERK phosphorylation, this has been shown to be dependent upon G i/o -derived βγ subunits in fibroblasts, and therefore, this would still indicate ligand bias at the level of the G protein (Daub et al., 1996; Tveteraas et al., 2016) .
In summary, we have characterized the calcium and ERK responses downstream of the LPA 1 receptor for a number of different LPA analogues and demonstrated that there is signalling bias between these pathways in HLF. As these experiments were performed in a native cell background almost exclusively expressing the LPA 1 receptor, using a range of endogenous ligands, they could be indicative of the native in vivo situation in the lung, which may also have clinical relevance. The importance of LPA as a key signalling molecule is shown by its widespread occurrence in biological fluids and in the majority of the tissues in the body. It is also becoming increasingly important for drug discovery efforts and has been shown to play an important role in the pathogenesis of a range of diseases, with fibrosis, rheumatoid arthritis, neuropathic pain, cardiovascular disease and cancer being key areas of interest (Choi et al., 2010; Lin et al., 2010; Tigyi, 2010; Yanagida and Ishii, 2011; Velasco et al., 2016) . Due to the diversity in the LPA analogues, it is possible that levels of specific molecular analogues of LPA are de-regulated in certain conditions and the ligand bias could be explored in developing selective ligands for therapeutic applications. Here, we have investigated signalling bias for the LPA 1 receptor between calcium mobilization and ERK phosphorylation. However, there is also the potential for signalling through Transduction ratios (LogR) and BF were calculated using the equations described by Van Der Westhuizen et al. (2014) from data plotted using the operational model. Data used were obtained from calcium experiments performed in the presence of PTx (G q/11 -dependent) and ERK phosphorylation performed in the absence of PTx (G i/o -dependent), and calculations performed using either 18:1 or 17:0 LPA as the reference ligand. Data are expressed as the mean AE SEM of three independent experiments. Data were analysed in a pairwise manner using a two-tailed unpaired Student's t-test [on ΔΔLogR] to determine the significance of the ligand biases. *P < 0.05.
Gprotein-independent pathways such as β-arrestin. These data were all generated in human primary cells, which endogenously express the LPA 1 receptor, as well as the relevant effector proteins. For this reason, we believe the bias we have detected may be more relevant for therapeutic applications. Unfortunately, it is still difficult to monitor β-arrestin recruitment or receptor internalization without the need to transfect labelled proteins, which may predispose the signalling towards these over-expressed pathways. For this reason, we have not monitored these pathways in this study. Together, these data demonstrate the importance of considering not only the LPA isoform associated with health and disease but the receptor signalling pathways that are activated as well. 
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